205 related articles for article (PubMed ID: 35267068)
1. Farnesoid X receptor (FXR) agonists induce hepatocellular apoptosis and impair hepatic functions via FXR/SHP pathway.
Zhang T; Feng S; Li J; Wu Z; Deng Q; Yang W; Li J; Pan G
Arch Toxicol; 2022 Jun; 96(6):1829-1843. PubMed ID: 35267068
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
[TBL] [Abstract][Full Text] [Related]
3. Obeticholic acid protects against carbon tetrachloride-induced acute liver injury and inflammation.
Zhang DG; Zhang C; Wang JX; Wang BW; Wang H; Zhang ZH; Chen YH; Lu Y; Tao L; Wang JQ; Chen X; Xu DX
Toxicol Appl Pharmacol; 2017 Jan; 314():39-47. PubMed ID: 27865854
[TBL] [Abstract][Full Text] [Related]
4. Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice.
Singh AB; Dong B; Kraemer FB; Xu Y; Zhang Y; Liu J
Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2448-2459. PubMed ID: 30354208
[TBL] [Abstract][Full Text] [Related]
5. Regulation of Intestinal UDP-Glucuronosyltransferase 1A1 by the Farnesoid X Receptor Agonist Obeticholic Acid Is Controlled by Constitutive Androstane Receptor through Intestinal Maturation.
Weber AA; Mennillo E; Yang X; van der Schoor LWE; Jonker JW; Chen S; Tukey RH
Drug Metab Dispos; 2021 Jan; 49(1):12-19. PubMed ID: 33154041
[TBL] [Abstract][Full Text] [Related]
6. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.
Jung H; Chen J; Hu X; Sun H; Wu SY; Chiang CM; Kemper B; Chen LF; Kemper JK
JCI Insight; 2020 Dec; 6(1):. PubMed ID: 33290278
[TBL] [Abstract][Full Text] [Related]
7. Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.
Adorini L; Rigbolt K; Feigh M; Roth J; Erickson M
PLoS One; 2024; 19(4):e0300809. PubMed ID: 38662778
[TBL] [Abstract][Full Text] [Related]
8. Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand.
Yu J; Yang K; Zheng J; Zhao W; Sun X
Cancer Gene Ther; 2021 Jun; 28(6):590-601. PubMed ID: 33046820
[TBL] [Abstract][Full Text] [Related]
9. Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis.
Carino A; Biagioli M; Marchianò S; Fiorucci C; Bordoni M; Roselli R; Di Giorgio C; Baldoni M; Ricci P; Monti MC; Morretta E; Zampella A; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Sep; 1865(9):158733. PubMed ID: 32371093
[TBL] [Abstract][Full Text] [Related]
10. A Short Review on Obeticholic Acid: An Effective Modulator of Farnesoid X Receptor.
Narayanan AK; Surendran S; Balakrishnan D; Gopalakrishnan U; Malick S; Valsan A; Philips CA; Watson CJE
Curr Rev Clin Exp Pharmacol; 2024; 19(3):225-233. PubMed ID: 38708917
[TBL] [Abstract][Full Text] [Related]
11. Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models.
Zhang Y; LaCerte C; Kansra S; Jackson JP; Brouwer KR; Edwards JE
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226620
[TBL] [Abstract][Full Text] [Related]
12. The FXR Agonist, Obeticholic Acid, Suppresses HCC Proliferation & Metastasis: Role of IL-6/STAT3 Signalling Pathway.
Attia YM; Tawfiq RA; Ali AA; Elmazar MM
Sci Rep; 2017 Oct; 7(1):12502. PubMed ID: 28970500
[TBL] [Abstract][Full Text] [Related]
13. Obeticholic Acid Ameliorates Valproic Acid-Induced Hepatic Steatosis and Oxidative Stress.
Gai Z; Krajnc E; Samodelov SL; Visentin M; Kullak-Ublick GA
Mol Pharmacol; 2020 May; 97(5):314-323. PubMed ID: 32098797
[TBL] [Abstract][Full Text] [Related]
14. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis.
Verbeke L; Mannaerts I; Schierwagen R; Govaere O; Klein S; Vander Elst I; Windmolders P; Farre R; Wenes M; Mazzone M; Nevens F; van Grunsven LA; Trebicka J; Laleman W
Sci Rep; 2016 Sep; 6():33453. PubMed ID: 27634375
[TBL] [Abstract][Full Text] [Related]
15. Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation.
Gai Z; Visentin M; Gui T; Zhao L; Thasler WE; Häusler S; Hartling I; Cremonesi A; Hiller C; Kullak-Ublick GA
Mol Pharmacol; 2018 Aug; 94(2):802-811. PubMed ID: 29743187
[TBL] [Abstract][Full Text] [Related]
16. 3β-Isoobeticholic acid efficiently activates the farnesoid X receptor (FXR) due to its epimerization to 3α-epimer by hepatic metabolism.
Stefela A; Kaspar M; Drastik M; Holas O; Hroch M; Smutny T; Skoda J; Hutníková M; Pandey AV; Micuda S; Kudova E; Pavek P
J Steroid Biochem Mol Biol; 2020 Sep; 202():105702. PubMed ID: 32505574
[TBL] [Abstract][Full Text] [Related]
17. Obeticholic acid attenuates the intestinal barrier disruption in a rat model of short bowel syndrome.
Hou L; Wang H; Yan M; Cai Y; Zheng R; Ma Y; Tang W; Jiang W
Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167221. PubMed ID: 38718845
[TBL] [Abstract][Full Text] [Related]
18. Disruption of TFGβ-SMAD3 pathway by the nuclear receptor SHP mediates the antifibrotic activities of BAR704, a novel highly selective FXR ligand.
Carino A; Biagioli M; Marchianò S; Scarpelli P; Zampella A; Limongelli V; Fiorucci S
Pharmacol Res; 2018 May; 131():17-31. PubMed ID: 29530598
[TBL] [Abstract][Full Text] [Related]
19. Unaltered Liver Regeneration in Post-Cholestatic Rats Treated with the FXR Agonist Obeticholic Acid.
de Haan LR; Verheij J; van Golen RF; Horneffer-van der Sluis V; Lewis MR; Beuers UHW; van Gulik TM; Olde Damink SWM; Schaap FG; Heger M; Olthof PB
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33578971
[No Abstract] [Full Text] [Related]
20. FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver.
Papazyan R; Liu X; Liu J; Dong B; Plummer EM; Lewis RD; Roth JD; Young MA
J Lipid Res; 2018 Jun; 59(6):982-993. PubMed ID: 29559521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
